Descovy or Truvada — Competitive Intelligence Brief

Descovy or Truvada (Descovy or Truvada) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor combination. Area: Infectious Disease / Virology.

phase 3 Nucleoside/nucleotide reverse transcriptase inhibitor combination HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule

Target snapshot

Descovy or Truvada (Descovy or Truvada) — Brigham and Women's Hospital. Descovy and Truvada are antiretroviral combinations that inhibit HIV reverse transcriptase and integrase to prevent viral replication and transmission.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Descovy or Truvada TARGET	Descovy or Truvada	Brigham and Women's Hospital	phase 3	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase, HIV integrase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Nevirapine, FTC, and Tenofovir	Nevirapine, FTC, and Tenofovir	University of Maryland, Baltimore	marketed	Antiretroviral combination (NNRTI + NRTI + NtRI)	HIV reverse transcriptase, HIV integrase
Immediate switch to TDF/FTC/RPV	Immediate switch to TDF/FTC/RPV	Azienda Ospedaliera San Gerardo di Monza	marketed	Antiretroviral combination therapy (NRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor combination class)

1. ViiV Healthcare · 2 drugs in this class
2. Brigham and Women's Hospital · 1 drug in this class
3. Fundacion IDEAA · 1 drug in this class
4. Janssen Sciences Ireland UC · 1 drug in this class
5. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
6. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
7. University of Chicago · 1 drug in this class
8. University of Washington · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class